Overview
Fmoc-alpha-aminoisobutyric acid is a valuable component in peptide synthesis, particularly for researchers looking to create complex peptide chains. This unusual amino acid serves as a building block, allowing you to introduce unique properties into your peptides. Sold in a convenient 5 g package, it’s an essential reagent for your laboratory needs.
Key Features
- High purity for reliable results
- Facilitates the incorporation of structural diversity in peptide synthesis
- Compatible with standard coupling protocols
- Ideal for applications in research and development
- Part of our comprehensive collection of analogs of Alanine, Glycine, Valine, and Leucine
Specifications
| Property | Details |
|---|---|
| Product Name | Fmoc-alpha-aminoisobutyric acid |
| CAS Number | [Enter CAS Number] |
| Weight | 5 g |
| Category | Analogs of Alanine, Glycine, Valine, and Leucine |
FAQ
What is Fmoc-alpha-aminoisobutyric acid used for?
Fmoc-alpha-aminoisobutyric acid is primarily used as a building block in peptide synthesis. Its unique structure allows for the introduction of diverse properties into peptides, making it suitable for various research applications.
How does this amino acid fit into peptide synthesis?
This amino acid can be easily incorporated into peptide chains using standard coupling methods, providing flexibility in designing peptides for specific functions and studies.
Can I find more unusual amino acids for peptide synthesis?
Yes, you can explore our full range of unusual amino acids, including options like Fmoc-(N-beta-allyloxycarbonyl)-L-alpha,beta-diaminopropionic acid and Fmoc-5,5,5-trifluoro-DL-leucine. These products contribute to the versatility of your peptide synthesis.
When you’re ready to enhance your research with Fmoc-alpha-aminoisobutyric acid, you can purchase it directly from our site. Don’t miss out on the chance to add this valuable amino acid to your toolkit today.
Related Products
Browse more in Analogs of Alanine, Glycine, Valine, and Leucine.




Reviews
There are no reviews yet.